Top Markets
#1 Akedo Akedo +111.38%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.38%
#4 Black Phoenix Black Phoenix +34.09%
#5 Velvet Velvet +33.20%
#6 Cross Cross +32.71%
#7 OVERTAKE OVERTAKE +17.22%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.83%
#9 Bitway Bitway +14.87%
#10 QANplatform QANplatform +14.54%
Coin of the day
Akedo Akedo
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
BNB Plus Corp. BNB Plus Corp.

BNB Plus Corp.

BNBX
Rang in Aktien #38647
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a... BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Aktienkurs
$0.09
Zuletzt synchronisiert: 2026-07-28
Marktkapitalisierung
$876.21K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-97.79%
Land
US
Handel BNB Plus Corp. (BNBX)

Kategorie

Healthcare
P/S-Verhältnis für BNB Plus Corp. (BNBX)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von BNB Plus Corp. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für BNB Plus Corp. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE